Matches in Wikidata for { <http://www.wikidata.org/entity/Q63571210> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- Q63571210 description "clinical trial" @default.
- Q63571210 description "ensayu clínicu" @default.
- Q63571210 description "klinisch onderzoek" @default.
- Q63571210 description "клінічне випробування" @default.
- Q63571210 name "A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors" @default.
- Q63571210 type Item @default.
- Q63571210 label "A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors" @default.
- Q63571210 prefLabel "A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors" @default.
- Q63571210 P1132 Q63571210-9AFF9287-06B9-456A-9D02-4BEA99610A71 @default.
- Q63571210 P1476 Q63571210-0A96F432-146B-4B66-A876-AEDA845CCE1A @default.
- Q63571210 P17 Q63571210-3A70E5DC-8AAA-4A14-B1F7-5CFCEBCF7EE9 @default.
- Q63571210 P17 Q63571210-6EEE40CD-F359-41E1-A8CF-4D6449FDA0F3 @default.
- Q63571210 P17 Q63571210-9E650738-465A-4806-B290-4988C077A74E @default.
- Q63571210 P17 Q63571210-D109BCF3-A345-404F-A4BB-4260F167319C @default.
- Q63571210 P17 Q63571210-D76B5859-6AFC-404A-8662-765D27F7AB18 @default.
- Q63571210 P2899 Q63571210-0D5386C2-6DC8-417B-83E0-E2EE341DA576 @default.
- Q63571210 P3098 Q63571210-76866D2B-AD10-4A6E-866B-257A5A52E318 @default.
- Q63571210 P31 Q63571210-DCB97218-6390-4533-A3D9-8B3EEA11B3BA @default.
- Q63571210 P4844 Q63571210-09AACE56-13DD-4AFE-B868-5756F5B575E5 @default.
- Q63571210 P4844 Q63571210-7AACB653-2874-4694-8CAE-8ADD1C2B824D @default.
- Q63571210 P4844 Q63571210-9DAC453B-0266-4402-B4F8-B014A56936B7 @default.
- Q63571210 P4844 Q63571210-B46B7323-B973-4423-BEB2-4B84162BE25A @default.
- Q63571210 P4844 Q63571210-DAA98A2E-4008-4596-86F4-6571E6015D54 @default.
- Q63571210 P4844 Q63571210-DB0AC05C-15E2-48C1-9F44-40858347718B @default.
- Q63571210 P4844 Q63571210-F1814F37-B8B9-4512-A290-82CF32B77B9C @default.
- Q63571210 P580 Q63571210-C7AB3F30-DAA9-465B-987C-E0360C7A44D5 @default.
- Q63571210 P582 Q63571210-08CA8D7E-2948-48DF-AA18-BA64465B22A2 @default.
- Q63571210 P6099 Q63571210-B2E0431A-D0AB-458A-8195-D8EFF31273BF @default.
- Q63571210 P6153 Q63571210-0DF56582-9BC2-4F2E-8774-9EDB2DAC117D @default.
- Q63571210 P6153 Q63571210-1A86044C-7EF9-442B-8E94-E04990E30F61 @default.
- Q63571210 P6153 Q63571210-2124F950-B39C-4D42-9C01-381D32B37117 @default.
- Q63571210 P6153 Q63571210-3BF6C4AB-FF7D-4844-B130-3FBE04BC3351 @default.
- Q63571210 P6153 Q63571210-41FAE97C-5819-4277-9E80-C56C6CFED23B @default.
- Q63571210 P6153 Q63571210-43316B0C-83C5-4D19-9057-D432A0903DA6 @default.
- Q63571210 P6153 Q63571210-44AE3BC3-3332-4481-ABE1-92A1EB4E4A98 @default.
- Q63571210 P6153 Q63571210-515B84C9-9E49-4D66-9DC8-11ABFD2DDFDA @default.
- Q63571210 P6153 Q63571210-5FAD3DB0-CA44-48C2-B526-C4669D24ACB2 @default.
- Q63571210 P6153 Q63571210-64F2B84C-BB74-4E97-AFC6-A0A39C05C9E0 @default.
- Q63571210 P6153 Q63571210-782F3692-182E-42BE-9BDA-5808BE55B798 @default.
- Q63571210 P6153 Q63571210-85262EE5-5C31-4980-BE4E-7390BAB7B509 @default.
- Q63571210 P6153 Q63571210-8DC31699-45BB-435C-BDC7-9D7877BF9E71 @default.
- Q63571210 P6153 Q63571210-95017FB7-0D4A-4F50-9C3E-CCCE91AA0D01 @default.
- Q63571210 P6153 Q63571210-978809ED-C121-46E6-8611-09798DFD77B9 @default.
- Q63571210 P6153 Q63571210-BC827A00-AEE3-4E7B-BDFC-6D67BF08AA01 @default.
- Q63571210 P6153 Q63571210-BE22B7A6-CC95-4F8E-8524-7756FC675FF1 @default.
- Q63571210 P6153 Q63571210-C09AED45-CEA2-4055-B2D5-4BE7B61F5D04 @default.
- Q63571210 P8363 Q63571210-F81C3EC4-D3B0-4C34-9E0F-95CB3E9A1FEE @default.
- Q63571210 P859 Q63571210-787496AC-638D-409C-8572-60168B433A73 @default.
- Q63571210 P1132 "+430" @default.
- Q63571210 P1476 "An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors" @default.
- Q63571210 P17 Q17 @default.
- Q63571210 P17 Q30 @default.
- Q63571210 P17 Q408 @default.
- Q63571210 P17 Q664 @default.
- Q63571210 P17 Q865 @default.
- Q63571210 P2899 "+18" @default.
- Q63571210 P3098 "NCT02715531" @default.
- Q63571210 P31 Q30612 @default.
- Q63571210 P4844 Q20707748 @default.
- Q63571210 P4844 Q412415 @default.
- Q63571210 P4844 Q413299 @default.
- Q63571210 P4844 Q414143 @default.
- Q63571210 P4844 Q420207 @default.
- Q63571210 P4844 Q422327 @default.
- Q63571210 P4844 Q423762 @default.
- Q63571210 P580 "2016-04-06T00:00:00Z" @default.
- Q63571210 P582 "2019-05-31T00:00:00Z" @default.
- Q63571210 P6099 Q5452194 @default.
- Q63571210 P6153 Q1130172 @default.
- Q63571210 P6153 Q1159198 @default.
- Q63571210 P6153 Q126412 @default.
- Q63571210 P6153 Q1418766 @default.
- Q63571210 P6153 Q192334 @default.
- Q63571210 P6153 Q2415975 @default.
- Q63571210 P6153 Q333886 @default.
- Q63571210 P6153 Q39988 @default.
- Q63571210 P6153 Q4403855 @default.
- Q63571210 P6153 Q4803501 @default.
- Q63571210 P6153 Q4819504 @default.
- Q63571210 P6153 Q4892499 @default.
- Q63571210 P6153 Q49112 @default.
- Q63571210 P6153 Q624119 @default.
- Q63571210 P6153 Q6806307 @default.
- Q63571210 P6153 Q706177 @default.
- Q63571210 P6153 Q7451677 @default.
- Q63571210 P6153 Q914024 @default.
- Q63571210 P8363 Q78089383 @default.
- Q63571210 P859 Q212646 @default.